All News

Finalist essay written by Catherine Gilmore nominating nurse Jackie Broadway-Duren, MSN, FNP-BC, from M.D. Anderson Cancer Center, for CURE's 2010 Extraordinary Healer Award contest.

Continued use of the targeted drug Avastin (bevacizumab), after initial treatment with the drug and chemotherapy, helped slow progression of advanced ovarian cancer, according to a phase 3 study.

An investigational drug, Crizotinib (PF-02341066), which targets a newly discovered gene mutation in lung tumors, showed dramatic results in a small phase 1 clinical trial of metastatic non-small cell lung cancer patients.

Interim results from a phase 3 trial showed that radiation added to androgen-deprivation therapy (ADT) increased overall survival and decreased the risk of death from prostate cancer.

For metastatic melanoma patients who were out of treatment options, the immune system-targeted drug ipilimumab extended their lives by nearly four months compared with an investigational vaccine called gp100.

A large randomized study contradicted that notion in advanced non-small cell lung cancer when data showed that the standard combination chemotherapy, usually given to younger patients, was effective and safe in elderly patients.

Navigating through the maze of disability insurance.